Petra Disterer
Petra Disterer
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion
A Rhie, L Kirby, N Sayer, R Wellesley, P Disterer, I Sylvester, A Gill, ...
Journal of Biological Chemistry 278 (41), 39697-39705, 2003
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
C Godfrey, LR Desviat, B Smedsrød, F Piétri‐Rouxel, MA Denti, P Disterer, ...
EMBO molecular medicine 9 (5), 545-557, 2017
Pathogenetic mechanisms of amyloid A amyloidosis
JP Simons, R Al-Shawi, S Ellmerich, I Speck, S Aslam, WL Hutchinson, ...
Proceedings of the National Academy of Sciences 110 (40), 16115-16120, 2013
Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant: implications for disease susceptibility to Creutzfeldt-Jakob disease
A Tahiri-Alaoui, AC Gill, P Disterer, W James
Journal of Biological Chemistry 279 (30), 31390-31397, 2004
Development of therapeutic splice-switching oligonucleotides
P Disterer, A Kryczka, Y Liu, YE Badi, JJ Wong, JS Owen, B Khoo
Human gene therapy 25 (7), 587-598, 2014
The presence of valine at residue 129 in human prion protein accelerates amyloid formation
I Baskakov, P Disterer, L Breydo, M Shaw, A Gill, W James, ...
FEBS letters 579 (12), 2589-2596, 2005
Multigene RNA vector based on coronavirus transcription
V Thiel, N Karl, B Schelle, P Disterer, I Klagge, SG Siddell
Journal of virology 77 (18), 9790-9798, 2003
Use of internally nuclease‐protected single‐strand DNA oligonucleotides and silencing of the mismatch repair protein, MSH2, enhances the replication of corrected cells …
I Papaioannou, P Disterer, JS Owen
The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2009
Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo
P Disterer, R Al-Shawi, S Ellmerich, SN Waddington, JS Owen, JP Simons, ...
Molecular Therapy 21 (3), 602-609, 2013
Distinct patterns of heparan sulphate in pancreatic islets suggest novel roles in paracrine islet regulation
A Theodoraki, Y Hu, S Poopalasundaram, A Oosterhof, SE Guimond, ...
Molecular and cellular endocrinology 399, 296-310, 2015
Validation of oligonucleotide-mediated gene editing
P Disterer, JP Simons, JS Owen
Gene Therapy 16 (6), 824-826, 2009
Oligonucleotide‐mediated gene editing is underestimated in cells expressing mutated green fluorescent protein and is positively associated with target protein expression
P Disterer, I Papaioannou, VC Evans, J Paul Simons, JS Owen
The journal of gene medicine 14 (2), 109-119, 2012
Antisense-mediated exon-skipping to induce gene knockdown
P Disterer, B Khoo
Exon Skipping: Methods and Protocols, 289-305, 2012
Gene Therapy for Apolipoprotein AI and HDL—The Ultimate Treatment for Atherosclerosis
P Disterer, E Osman, JS Owen
Vascular Complications in Human Disease: Mechanisms and Consequences, 197-212, 2008
Gene therapy for apolipoprotein AI and HDL-the ultimate treatment for atherosclerosis
P Disterer, E Osman, JS Owen
Springer Verlag, 2007
Methionine 129 variant of human prion protein oligomerizes more rapidly than the
A Tahiri-Alaoui, AC Gill, P Disterer, W James
Lancet 347, 921-925, 1992
Dieter C. Gruenert, PhD (1949–2016)
P Disterer, MA Kay, GC Parker
Nucleic Acid Therapeutics 26 (4), 266-267, 2016
APO-skip splice-switching oligonucleotides to treat familial hypercholesterolemia
P Disterer, JP Simons, JS Owen, B Khoo
HUMAN GENE THERAPY 24 (5), A31-A31, 2013
Altered sulfation patterns of heparan sulfate on FGFR1 signalling in INS1 cells
A Theodoraki, Y Hu, S Poopalasundaram, S Guimond, A Oosterhof, ...
DIABETIC MEDICINE 30, 33-34, 2013
British Society for Gene and Cell Therapy (BSGCT) Conference Abstracts Royal Holloway University of London 17–19 April, 2013
C Denning, GM Ellison, K Mitrophanous, L Seymour, JCI Belmonte, ...
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20